Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis

医学 肺癌 贝伐单抗 内科学 不良事件通用术语标准 肿瘤科 化疗 不利影响 癌症 实体瘤疗效评价标准 回顾性队列研究 靶向治疗 联合疗法 进行性疾病
作者
Ran Hu,Zhiting Zhao,Yue Shi,Meiqi Shi,Guohao Xia,Shaorong Yu,Jifeng Feng
出处
期刊:Journal of Thoracic Disease [AME Publishing Company]
卷期号:13 (5): 2959-2967 被引量:3
标识
DOI:10.21037/jtd-20-3520
摘要

EGFR-mutated lung cancer poorly responded to anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy. Whether patients with EGFR-mutated lung cancer can benefit from anti-PD-1/PD-L1 therapy combined with other drugs remains controversial. We retrospectively evaluated the safety and efficacy of the PD-1 inhibitor combined with other drugs (chemotherapy and/or bevacizumab) in patients with EGFR-mutated lung cancer, who have progressed on EGFR-TKI treatment to determine the activity of the anti-PD-1/PD-L1 therapy combined with chemotherapy or/and bevacizumab therapy in heavily treated patients with EGFR-mutated lung cancer.We identified 56 patients with EGFR-mutated lung cancer treated with PD-1/PD-L1 inhibitors alone or combined with the chemotherapy/bevacizumab therapy. The objective response rates were assessed using RECIST v1.1. Adverse events (AEs) were graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Academic Ethics Committee of Jiangsu Cancer Hospital. (NO. 2019 160), and individual consent for this retrospective analysis was waived.Objective responses were observed in 6 of 56 (10.7%) patients, and the disease control rate was 53.6% (30/56). The median progression-free survival (PFS) was 3.33 months with 95% CI of 1.58-5.08 months. No patient achieved a complete response. All six patients that achieved PR were treated with the PD-1 inhibitor combined with chemotherapy or bevacizumab therapy. Three of the six patients who achieved PR were treated with radiotherapy combined with PD-1 inhibitor-based therapy. Patients treated with the PD-1 inhibitor-based therapy as second-line therapy showed relatively longer PFS and higher objective response rates than those treated with PD-1 inhibitor-based therapy as third- or late-line therapy (PFS: 5.50 vs. 3.27 months, P=0.301; objective response rates: 25.0% vs. 6.82%, P=0.071). No additional AE profile was observed.The PD-1 inhibitor combined with the chemotherapy/bevacizumab therapy showed acceptable toxicity profile and moderate efficacy on heavily treated advanced EGFR-mutated lung cancer after the exhaustion of target therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ding应助科研通管家采纳,获得10
1秒前
Youdge应助科研通管家采纳,获得10
1秒前
上官若男应助科研通管家采纳,获得10
2秒前
2秒前
MchemG应助科研通管家采纳,获得10
2秒前
czh应助科研通管家采纳,获得10
2秒前
所所应助科研通管家采纳,获得10
2秒前
MchemG应助科研通管家采纳,获得10
2秒前
MchemG应助科研通管家采纳,获得10
2秒前
丘比特应助科研通管家采纳,获得10
2秒前
所所应助科研通管家采纳,获得10
2秒前
Lucas应助科研通管家采纳,获得10
2秒前
2秒前
2秒前
热心市民小红花应助哈哈采纳,获得50
3秒前
NexusExplorer应助Skuld采纳,获得10
3秒前
starry完成签到 ,获得积分10
4秒前
大个应助kaoyikaoli采纳,获得10
4秒前
BIT_lulu完成签到,获得积分10
5秒前
6秒前
Yueee发布了新的文献求助10
6秒前
Lucas应助张道恒采纳,获得10
7秒前
量子星尘发布了新的文献求助10
7秒前
WQ发布了新的文献求助10
8秒前
烟花应助momo采纳,获得10
8秒前
健康的青槐完成签到 ,获得积分10
8秒前
林白生完成签到,获得积分10
11秒前
Valiant发布了新的文献求助10
11秒前
12秒前
champion完成签到 ,获得积分10
13秒前
江川锦鲤完成签到,获得积分10
14秒前
aigj完成签到 ,获得积分10
15秒前
早起睡个回笼觉完成签到,获得积分10
16秒前
16秒前
18秒前
科研杰克完成签到,获得积分10
18秒前
秃顶双马尾完成签到,获得积分10
19秒前
忐忑的行天完成签到,获得积分20
19秒前
科研狗完成签到,获得积分10
19秒前
SaiKeery发布了新的文献求助10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988920
求助须知:如何正确求助?哪些是违规求助? 3531290
关于积分的说明 11253247
捐赠科研通 3269903
什么是DOI,文献DOI怎么找? 1804830
邀请新用户注册赠送积分活动 882027
科研通“疑难数据库(出版商)”最低求助积分说明 809052